ArticleFrontiers in oncology2025
Establishment and validation of a prognostic risk model based on ADME-related genes in breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The processes of absorption, distribution, metabolic action, and elimination (ADME) affect the advancement of cancer and the development of resistance to therapies. This study examined ADME-related genes in breast cancer (BRCA) mechanisms and their associations with BRCA. Methods: BRCA datasets were analyzed to identify genes with differential expression in BRCA compared to normal tissues, focusing on ADME-related genes (ADME-RGs). Stepwise regression analyses identified prognostic genes, which were used to develop a risk assessment model. BRCA patients were scored and classified into risk categories, with survival outcomes compared across groups. A predictive model incorporating key prognostic indicators estimated patient survival rates. Mechanisms were explored through enrichment analysis, immune profiling, and drug sensitivity testing. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot (WB) methodologies were employed to determine the transcription and translation levels of the six genes, with immunohistochemistry (IHC) used to validate the variations in their expression profiles. Results: Findings indicated that six predictive genes were pinpointed which established a risk stratification model, categorizing individuals into groups with either high or low risk, whereas those in the low-risk category demonstrated improved survival outcomes. A nomogram was created for precise prediction. Analysis of enrichment pinpointed processes, including metabolism of arachidonic and fatty acids, regulation of cellular division, proteasomal activity, and breakdown of tyrosine. Immune infiltration analysis showed distinct profiles for seven cell types between risk groups. Drug sensitivity analysis revealed GW.441756, imatinib, and WH.4.023 were more effective in the low-risk group, with varying sensitivities to other drugs in the high-risk group. The qRT-PCR, WB, and IHC results matched the bioinformatics analysis, showing upregulated ATP7B expression in BRCA, indicating the high prognostic potential of the identified genes. Conclusions: ADME-related prognostic genes (GSTM2, ADHFE1, ALDH2, NOS1, ATP7B, and ALDH3A1) are implicated in BRCA pathogenesis, suggesting new therapeutic strategies for BRCA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.